In summary, this study demonstrated that overactivation of Akt is associated with MEK inhibitor resistance in colorectal cancer cells harboring KRAS or BRAF mutations and that Akt inhibitor overcame MEK inhibitor resistance. This evidence concerns the gene MAP2K7 and colorectal cancer.